Erbitux

Cetuximab (Erbitux ) Merck mAb EGFR Metastatic colorectal cancer... [Pg.1193]

Cetuximab (Erbitux) Chimeric antibody, IgGi EGFR Ligand competition ADCC CRC SSCHN... [Pg.1255]

Antibodies Avastin, Bexxar, Erbitux, Herceptin, Humaspect, Humira, Mabcampath/Campath-Hl, Mabthera/ Rituxan, Mylotarg, Neutrospec, Oncoscint, Orthoclone OKT-3, Prostascint, Raptiva, Remicade, Simulect, Synagis, Xolair, Zenapax, Zevalin... [Pg.32]

Erbitux (cetuximab chimaeric antibody raised ImClone Systems Treatment of EGF receptor-... [Pg.381]

Cetuzimab (Erbitux) Monoclonal antibody against EGF receptor Refractory colorectal cancer in combination with irinotecan Randomized Phase II trial... [Pg.447]

The three monoclonal antibodies approved, noted in Table 23.1, in the last 7 years for treatment of patients with cancer include Alemtuzumab (Campath M) (Genzyme Corporation, Cambridge, MA, U.S.A.), Cetuzimab (Erbitux ) (ImClone Corporation, Branchburg, NJ, U.S.A.), and bevacizumab (Avastin ) (Genentech, South San Francisco, CA, U.S.A.). [Pg.449]

Another creative trial design was performed for the pivotal trial for approval of the monoclonal antibody cetuzimab (Erbitux). The clinical trial was based on the preclinical evidence. Erbitux was synergistic in animal model systems. [Pg.451]

Erbitux Cetuximab Bristol Myers Squibb, New York, NY /Imclone, New York, NY Anti-EGFR Colon cancer 2004... [Pg.580]

Cancer Antibodies Metastatic cancer, lymphoma Herceptin, Avastin, Rituxan, Erbitux, Procrit, Gleevec, Sutent... [Pg.96]

Cetuximab Erbitux Chimeric IgGl k anti-EGF receptor EGFR-expressing metastatic colorectal cancer 2003 Switzerland... [Pg.114]

Cetuximab (Erbitux) is a monoclonal antibody against the epidermal growth factor receptor, EGFR. It is approved for treatment of colorectal cancer. The development of Erbitux was much in the news in 2004 as a result of insider stock trading at ImClone in the face of an initial turndown by the FDA. The former head of ImClone, Sam Waksal, is spending a term of 7 years in jail for his role in the affair. Martha Stewart completed a jail term of several months in the same case. Erbitux was subsequently approved by the FDA on the basis of additional clinical information. [Pg.349]

Cetuximab [Erbitux] Colorectal carcinoma Rash fever infection dyspnea Gl distress [nausea, vomiting, diarrhea]... [Pg.578]

Cetuximab Erbitux Metastasized colorectal carcinoma (EGFR-positive) 2004... [Pg.88]

Erbitux Cetuximab Chimeric IgGi EGFR Colorectal cancer IV 250 mg/m2 Weekly... [Pg.312]

Imclone Systems Inc. and Bristol-Myers Squibb Corp. 2004. Erbitux prescribing information. [Pg.326]

Currently, cetuximab (Erbitux ) is indicated for the treatment of patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. Depending on the country, cetuximab is approved in combination with irinotecan or in addition as monotherapy. The approved dosing regimen consists of an initial dose of 400 mg/m2 body surface area (BSA), followed by weekly doses of 250 mg/m2. The (intravenous IV) infusion durations are 2 h for the initial infusion, and 1 h for the subsequent weekly infusions. [Pg.353]

A. Kovar. 2004. Pharmacokinetics of cetux-imab (Erbitux ) after single and multiple intravenous doses in cancer patients. AAPS Journal 6 4046. [Pg.371]

A. Kovar, and E. Raymond. 2005. Pharmacokinetic profile of cetuximab (Erbitux ) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur. J. Cancer 41 1739-1745. [Pg.371]

Erbitux /Cetuximab Immunoglobulin G1 Head, neck, and colorectal cancer... [Pg.396]

Imclone System Erbitux (Cetumimab) Chimeric Antineoplastic 2004... [Pg.419]

See also in sourсe #XX -- [ Pg.349 ]

See also in sourсe #XX -- [ Pg.107 ]

See also in sourсe #XX -- [ Pg.17 , Pg.85 ]

See also in sourсe #XX -- [ Pg.107 ]

See also in sourсe #XX -- [ Pg.578 ]

See also in sourсe #XX -- [ Pg.419 ]

See also in sourсe #XX -- [ Pg.179 ]

See also in sourсe #XX -- [ Pg.120 ]

See also in sourсe #XX -- [ Pg.401 ]

See also in sourсe #XX -- [ Pg.904 ]

See also in sourсe #XX -- [ Pg.107 ]

See also in sourсe #XX -- [ Pg.353 ]

See also in sourсe #XX -- [ Pg.632 , Pg.633 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...